383 results about "Rat model" patented technology

The invention belongs to the technical field of biomedical materials, and particularly relates to adipose-derived mesenchymal stem cell loaded conductive hydrogel and a preparation method and application thereof, the preparation method comprises the following steps: step S1, after hyaluronic acid is subjected to oxidation treatment, dopamine is grafted to oxidized hyaluronic acid, and oxidized hyaluronic acid-dopamine is obtained; step S2, carrying out amination treatment on gelatin to obtain aminated gelatin; s3, mixing the oxidized hyaluronic acid-dopamine with the aminated gelatin, and carrying out Schiff base crosslinking, so as to obtain hydrogel; and step S4, loading the adipose tissue-derived stromal cells by using the hydrogel. Dopamine is grafted on an oxidized hyaluronic acid macromolecular chain through amidation reaction, the hydrophilicity and the electrical property of the macromolecular chain are improved, a catechol structure is provided to provide possibility for iron ion coordination, the tissue adhesion, the injectability, the mechanical property and the electrical conductivity of the hydrogel are improved, and the hydrogel can be applied to the field of biomedical materials. After being applied to a spinal cord injury rat model, the functional recovery can be promoted.

The invention relates to the technical field of image recognition, in particular to an adhesion focus positioning method for an endometriosis rat model, which comprises the following steps of: firstly, adjusting a clustering distance according to color difference between saturation connected domains and a position inertial system, and clustering to obtain a connected domain cluster; due to the fact that the connected domain clusters contain the ectopic glands, the clusters need to be screened to obtain the ectopic glands, the gland probability of each connected domain cluster is obtained according to the characteristic that columnar epithelial cells are distributed on the inner walls of the ectopic glands, and the possibility that each connected domain cluster belongs to the ectopic glands is judged; due to the fact that the ectopic glands are distributed in a concentrated mode, the abnormal probability of the connected domain clusters is obtained through the aggregation of the connected domain clusters with the high gland probability, the possibility that the connected domain clusters belong to the abnormal ectopic glands is further judged, and the focus positioning accuracy of the endometriosis rat model is higher.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

The invention discloses a bone joint repairing composition containing stem cell vesicles and application of the bone joint repairing composition, and relates to the technical field of bone joint repairing compositions.The bone joint repairing composition is prepared from, by weight, 90-110 parts of stem cell vesicles and 41-57 parts of thelenota ananas saponin Ananaside A. The stem cell vesicles and the thelenota ananas saponin Ananaside A are combined to form the bone joint repairing composition. The stem cell vesicles are extracellular vesicles derived from human amniotic mesenchymal stem cells. According to the bone joint repairing composition provided by the invention, the stem cell vesicles and the thelenota ananas saponin in a proper proportion are matched for use, so that the synergistic interaction between the stem cell vesicles and the thelenota ananas saponin is realized. Animal experiments show that the composition has a remarkable repairing effect on a rat model with bone and joint injuries, can effectively relieve bone and joint pain symptoms of rats, not only widens the application field of human amniotic mesenchymal stem cell-derived extracellular vesicles, but also provides a new clinical treatment means for bone and joint repairing.

The invention relates to the field of medical application, in particular to application of nerve-soothing and brain-strengthening liquid to preparation of medicine for treating or preventing chronic fatigue syndrome. According to the invention, the nerve-soothing and brain-strengthening liquid is used for research on treatment or prevention of chronic fatigue syndrome for the first time. By establishing an intraperitoneal injection polyinosinic-cytidylic acid composite swimming induced CFS mouse model and a multi-factor composite stress induced CFS rat model, and by means of an exhaustive swimming experiment, a tail suspension experiment, a mechanical pain threshold, a Bannes maze and a pentobarbital sodium sleep experiment, an endocrine function, an immunologic function, skeletal muscle energy metabolism and other modes are detected, and the skeletal muscle energy metabolism can be detected. It is found that the nerve soothing and brain strengthening liquid can improve the CFS symptoms shown by mice and rats of the two models.

The invention discloses a method for establishing a hypoperfusion cerebral infarction model, which is used for simulating a clinical cerebral infarction animal model caused by low blood pressure by adopting a method for establishing a model for combining hypotension with improved middle cerebral artery occlusion (MCAO) rats. Compared with the prior art, the technical method that existing bilateral carotid artery ligation can only simulate chronic cerebral ischemia, ischemic infarction lesions are not formed, and hypoperfusion cerebral infarction cannot be simulated is broken through, the composite method that blood pressure reduction is combined with MCAO improvement is used for the first time, and the clinical common pathological state of cerebral blood flow hypoperfusion cerebral infarction caused by hypotension is simulated. According to the invention, the pathologic process of occurrence and development of the disease and the pharmacology of the drug are researched, and the drug action mechanism is explained; a reliable animal model is provided for new drug research and development.

The invention belongs to the technical field of biology, and particularly relates to casein phosphopeptides for promoting absorption of calcium, iron and zinc minerals and improving bone health. Casein phosphopeptides containing high-activity peptide fragments are obtained through an optimization process, six mineral elements of calcium, magnesium, copper, iron, zinc and manganese serve as research objects, firstly, mineral utilization of CPP is evaluated through a mineral deficiency rat model, the content of Ca, Mg, Cu, Fe, Zn and Mn in thighbones is increased by 7.12%, 3.56%, 20.76%, 15.84%, 9.94% and 67.12% respectively when the CPP is eaten by 7mg / kg.d; secondly, screening a peptide fragment with calcium absorption promoting activity from the CPP by utilizing a molecular docking technology, and performing functional verification; the invention aims to reveal the action effect of CPP in mineral absorption and utilization from cell and animal levels, and provides a theoretical basis for functional development of CPP.

The invention discloses a biomarker related to diabetic neuralgia and application of the biomarker. The biomarker is IGFBPs or CD324. According to the application, a DNP (Diabetic Neuralgia) rat model is constructed, the DIA and DDA combined technology is adopted, DNP model rats are subjected to serum proteome detection, and through analysis, screening and verification, compared with normal group rats, the expression level of IGFBPs or CD324 in serum of the DNP model rats has significant difference; according to the method, IGFBPs or CD324 is taken as a biomarker, a working characteristic curve (ROC) of a subject is drawn at the same time, and IGFBPs or CD324 is evaluated according to area under the curve (AUC) to have excellent diagnostic efficiency when applied to diabetic neuralgia as the biomarker, so that a new biomarker can be provided for auxiliary diagnosis of diabetic neuralgia, and clinical diagnosis of diabetic neuralgia is more convenient and accurate.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention discloses a construction method and application of a child inflammatory bowel disease rat model. The construction method comprises the following specific steps: smearing a 3% w / v oxazolone pre-sensitizing solution on the skin of a rat for pre-sensitization, and continuously performing repeated intermittent enema with a 1% w / v oxazolone enema. The model accords with the clinical manifestation and pathological characteristics of the children inflammatory bowel disease, and is a better model for researching the children inflammatory bowel disease.

The invention relates to the technical field of biology and new medicine, in particular to a preparation method, an identification method and a histopathologic analysis method of a rat uterus scar diverticulum model. The preparation method of the rat uterus scar diverticulum model comprises the following steps: sequentially simulating rat pregnancy by using female progestational hormone, and infecting a uterus incision by using group B streptococcus (GBS) to obtain the rat uterus scar diverticulum model. The preparation method comprises the following steps: constructing a pseudopregnant rat model; preparing a GBS bacterial solution with a certain concentration, and immersing 3-0 silk threads with the length of about 1cm into the bacterial solution for 24 hours for later use; an incision with the length of about 2 cm is formed in the uterus on the two sides of the rat, and the incision is sutured discontinuously by an absorbable line. The simulated pregnant mouse is used, the influence of uterine hyperemia during human delivery and hormone change after female progestational hormone withdrawal on the uterine microenvironment is met, the formation of the human uterine scar diverticulum simulated by using the group B streptococcus infection incision is related to cesarean delivery incision infection, and therefore the success rate of the obtained model is high.

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.

The invention discloses a method for constructing a polycystic ovarian syndrome (PCOS) rat model with reduced sex hormone binding globulin (SHBG) on the basis of ruminococcus aureus with the preservation number of ATCC29149, and belongs to the technical field of animal models. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the dosage is 0.2-1 mL / 100 g, the intragastric administration frequency is one time per day to two times per week, and the time lasts for 4-8 weeks, such that the SHBG synthesis of the rat liver is induced to decrease, and the PCOS pathological characteristics such as testosterone level increase, estrus cycle disorder, ovarian polycystic change, insulin resistance and the like are initiated; the problem that a traditional hormone induction method does not conform to the physiological status is solved, the modeling period of a high-fat diet induction method is shortened, and an efficient experimental tool is provided for PCOS mechanism research and drug development.

The invention relates to a construction method and application of a periodontitis rat model, and the construction method comprises the following steps: firstly, performing toxoplasma gondii infection on rats, then performing porphyromonas gingivalis and treponema denticola co-infection on the toxoplasma gondii infected rats, and establishing the periodontitis rat model. The periodontitis animal model is rapidly and stably obtained through the synergistic effect of the porphyromonas gingivalis, the treponema denticola and the toxoplasma gondii, and the constructed periodontitis model is highly consistent with the symptoms and signs of human periodontitis, can reflect the systematicness and severity of periodontitis, and has a good application prospect. And the method has the advantages of high modeling speed, high success rate and good repeatability, and is convenient for researching infection, development mechanism and prevention and treatment process of periodontitis.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

The invention belongs to the technical field of biology, and particularly relates to casein source heptapeptide for promoting calcium absorption and utilization and application of the casein source heptapeptide. The CPP containing the high-activity peptide fragment is obtained through an optimization process, and the influence of the CPP on mineral absorption and conversion is evaluated by utilizing a mineral deficiency rat model; then, heptapeptide with calcium absorption promoting activity is screened out from the CPP in combination with peptiomics and molecular docking technologies, functional verification is carried out, it is found that when the VAPFPEV is 2 mu M, the Ca < 2 + > transport amount is remarkably increased by 25.25%, meanwhile, zebra fish experiments show that intervention of the VAPFPEV effectively reverses reduction of an accumulated optical density value caused by dexamethasone, and compared with a module making set, the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the The skull accumulative optical density value of a VAPFPEV (1-20 [mu] M) processing group is obviously increased. It is shown that VAPFPEV can effectively promote Ca < 2 + > transfer and absorption, improve the osteoporosis symptom of zebra fish and increase deposition of calcium in bones.

The invention relates to an N-acetyl-D-glucosamine composition with an anti-tumor effect and application of the N-acetyl-D-glucosamine composition, and relates to the technical field of medicines and health care products, the N-acetyl-D-glucosamine composition with the anti-tumor effect comprises the following raw materials by weight: 17-29 parts of N-acetyl-D-glucosamine and 5-10 parts of an extract of Tongshan. According to the invention, the N-acetyl-D-glucosamine and the extract in a proper proportion are matched for use for the first time, so that the synergistic interaction of the N-acetyl-D-glucosamine and the extract is realized. In-vitro animal anti-tumor experiments show that the N-acetyl-D-glucosamine composition provided by the invention can significantly reduce the tumor volume in a rat model, provides a new way for clinical treatment of tumor patients, and has a wide application prospect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a new application of a Homai black-bone chicken Baifeng pill in preparation of a medicine for treating premature ovarian failure. According to the invention, a chemotherapy-induced premature ovarian failure rat model is established by intraperitoneal injection of cis-platinum, an immune premature ovarian failure mouse model is established by subcutaneous multi-point injection of mouse zona pellucida polypeptide 3 (pZP3), and the influence of Jianjing black-bone chicken Baifeng pills on animal estrus cycles, visceral organ coefficients, serum sex hormone levels and ovarian histopathologic changes of the two models is observed. The treatment effect of the Hoojing black-bone chicken Baifeng pill on the premature ovarian failure is verified and defined, the new clinical application of the medicine is expanded, and a new treatment medicine and means are provided for treating the premature ovarian failure, so that a technical support is provided for clinical precise medication.

The invention discloses a construction method and application of a Keman ataxia rat model, and belongs to the technical field of animal models. The construction method of the Keman ataxia rat model comprises the step of mutating the 38th nucleotide of the ATCAY gene exon 3 of a rat from G to A. The constructed Kemann ataxia rat model provides a research mode tool for researching the function of the ATCAY gene in Kemann ataxia and screening or preparing medicines for preventing or treating Kemann ataxia.

The invention discloses a polylipoic acid-based elastic patch capable of inducing adhesion in a wet environment as well as a preparation method and application of the polylipoic acid-based elastic patch. The polylipoic acid-based elastic adhesion patch can be obtained by simply concentrating and evaporating a mixed solution of lipoic acid and methacrylated gelatin. Due to the introduction of a methacrylated gelatin polymer chain, the layered crystal structure of an original lipoic acid-based polymer is reduced, so that the water sensitivity of the lipoic acid-based polymer is reduced, the release time of lipoic acid active molecules is prolonged, and a small amount of layered crystal structures are reserved in the polylipoic acid-based elastic adhesion patch; therefore, non-adhesion and rigidity are realized in a dry environment. Once exposed to water or body fluid, the hydrophilic polymer backbone of the patch can quickly absorb moisture, the entry of water molecules destroys the layered crystal structure, resulting in softness and adhesion of the patch. In a rat model with ligation of periodontitis, the patch can effectively relieve inflammation and inhibit alveolar bone resorption.

The invention discloses an establishment method and application of a traumatic hemorrhagic sudden cardiac arrest rat model, a rat is used as an experimental subject, a researcher can accurately adjust the hemorrhagic degree in an animal model by controlling the bloodletting speed and amount to better control experimental conditions, the repeatability and reliability of experimental results are ensured, and the method has the advantages of being high in operability and high in reliability. In the model building process, not only is the factor of blood loss considered, but also tissue damage caused by laparotomy is combined, physiological changes under the combined action of multiple factors after trauma are reflected more comprehensively, and the complexity and authenticity of the model are improved; the method has the advantages that the operation is simple, the experiment cost is lower, the repeatability is high, the scale and frequency of cardiac arrest research experiments are not limited, the experiment result has higher reliability and generalizability, and the method not only can be used for basic medical research and exploration of the pathophysiology mechanism of traumatic hemorrhagic shock, but also is suitable for pharmacological research, and has a wide application prospect. The effectiveness of new drugs or therapies for improving prognosis is assessed.

The invention discloses a noninvasive chronic abacterial prostatitis rat model making device which comprises a multifunctional operation base, a lifting stand column, a rat posture adjusting mechanism, a rat fixing plate, a lifting support, a pitching angle adjusting mechanism and a rat prostate multi-mode stimulator. The lifting support is fixed on the base, the pitching angle adjusting mechanism is fixed on the lifting support, the rat prostate multi-mode stimulator is fixed on the pitching angle adjusting mechanism, the rat posture adjusting mechanism is fixed on the multifunctional operation base, and the rat fixing plate is fixed on the rat posture adjusting mechanism. According to the device, the chronic abacterial prostatitis rat model is constructed by combining prostate local thermal stimulation with prostate local high-frequency vibration stimulation, the prostate tissue of the rat is noninvasive in the whole modeling process, and the problem of modeling failure or low success rate caused by introduction of bacteria in the injection puncture process is avoided.

The invention belongs to the technical field of biological medicine, and particularly relates to a composition for preventing and treating polycystic ovarian syndrome and application, the composition comprises the following active components: tripterygium wilfordii polysaccharide, dendrobium fimbriatum polysaccharide, hericium erinaceus polysaccharide, lycium barbarum polysaccharide and ackermania muciniphila bacterial suspension. A female SD rat model induced by letrozole and a high-glucose and high-fat feed is adopted to prove the application of Ackermania muciniphila in resisting the polycystic ovarian syndrome, the test method is safe and reliable, the test result is accurate, the curative effect is remarkable, and the invention provides a composition capable of inhibiting or improving or treating the polycystic ovarian syndrome. Compared with single oral administration of ackermania muciniphila suspension, the composition provided by the invention has the advantages that the effect is better, the components of the composition are safer, the technical problem that side effects exist when existing chemical synthesis medicines are used for treating the polycystic ovarian syndrome is solved, and the composition has a good application prospect.

The invention provides a pharmaceutical composition and application thereof in preparation of a compound preparation, and belongs to the field of medicines. The pharmaceutical composition comprises a potassium ion channel opener, a 5 alpha-reductase inhibitor and a phosphodiesterase 5 inhibitor. The pharmaceutical composition can synergistically promote treatment of androgen dependent diseases or prevention of complications, and by taking the pharmaceutical composition of minoxidil, finasteride and tadalafil as an example, the effects in a benign prostatic hyperplasia rat model and an androgenic alopecia mouse model are verified, which indicates that the minoxidil, finasteride and tadalafil have a synergistic interaction effect, and the pharmaceutical composition can be used for treating the androgen dependent diseases or preventing the complications. Good clinical application prospects are realized.

A use of a compound represented by formula I, or a cis-trans isomer, enantiomer, diastereomer, racemate, solvate, hydrate, pharmaceutically acceptable salt or prodrug thereof in the preparation of a drug for preventing, relieving, assisting in treating, or treating lung injury. Upon verification, administration of the compound represented by formula I can significantly reduce proinflammatory cytokines, i.e., tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), of a rat model of acute lung injury, reduce the infiltration of inflammatory cells (comprising monocytes / macrophages, lymphocytes, and neutrophils) in lung tissues, relieve pathological injury of the lung tissues, improve the lung function, and increase the survival rate of comorbidities of acute lung injury. The compound represented by formula I can be used for preventing, relieving, assisting in treating, or treating lung injury, especially acute lung injury or comorbidities thereof, or acute respiratory distress syndrome or comorbidities thereof.

The invention discloses an application of 4-octyl itaconic acid (4-OI) in preparation of a medicine for improving pulmonary arterial hypertension (PAH). In-vivo experiments show that 4-OI can significantly reduce pulmonary vascular wall thickening and collagen deposition of a PAH rat model, and effectively improve PAH and vascular remodeling. In-vitro experiments further reveal that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting a PERK-eIF2alpha pathway, further blocks SM22 dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transformation (EndMT) processes, finally inhibits vascular remodeling, and plays a role in treating PAH. The three key pathological processes of ERS, EndMT and vascular remodeling are closely linked, a new perspective is provided for deeply understanding the correlation among oxidative stress, endothelial dysfunction and vascular structure change in PAH, meanwhile, a theoretical foundation is laid for developing PAH and vascular remodeling accurate treatment drugs, and clinical transformation value is achieved.

The invention discloses a polypeptide with blood pressure lowering and oxidation resisting effects as well as a related product and application thereof, and relates to the technical field of biology. According to the invention, casein is taken as a raw material, and the milk-derived active peptide ALPQY is successfully obtained through multi-enzyme hydrolysis, separation, purification and identification. In-vitro activity evaluation results show that the polypeptide not only has strong ACE inhibitory activity, but also can effectively scavenge free radicals; the ACE inhibition IC50 value is 35.56 mu M, the free radical scavenging TEAC value is 1.83 mu mol TE / mu mol, and compared with similar polypeptides, the polypeptide has better ACE inhibition effect and free radical scavenging effect. In-vivo antihypertensive evaluation is carried out through a spontaneous hypertension rat model, it is also shown that the compound has a good antihypertensive effect, and the compound can be used for preparing products related to antihypertensive and / or antioxidation.

The invention discloses a novel protein marker for judging muscle injury degree as well as an obtaining method and application of the novel protein marker. The novel protein marker comprises at least one of 36 proteins; the invention discloses a novel protein marker obtaining method. The method specifically comprises the following steps: establishing experimental rat models with different muscle injury degrees, collecting plasma of each group of rats, performing proteomics detection, comparing differences to obtain candidate protein markers, verifying the candidate protein markers by using blood of patients with different clinical muscle injury degrees, and determining a diagnosis reference interval range of the candidate protein markers; according to the application of the proteomic marker, the novel protein marker is used for preparing a kit or detecting and judging the muscle injury degree through a mass spectrum method or any other method. According to the method, a new basis is provided for judging the muscle injury degree, and the muscle injury degree can be quantified conveniently.

The invention discloses a detection method for influence of PGRN regulation on cerebellar synaptic development of ASD rats, and relates to the technical field of autism spectrum disorders. The method specifically comprises the following steps: step 1, breeding an experimental rat; 60 Sprague-Dawley rats in the childbearing age are purchased, the female-male ratio is 2: 1, the rats freely eat and drink water, and the rats are fed for three to five weeks; step 2, preparing a VPA induced ASD rat model; experimental rats are subjected to fertilization culture, female rats are randomly divided into two groups after being fertilized for 12.5 days, a VPA solution is injected into the VPA group through the abdominal cavity, and sterile normal saline with the same volume is injected into the control group. The detection method shows that the PGRN can obviously relieve VPA-induced dyskinesia and autism-like behaviors of ASD rats and relieve cerebellar Purkinje cell synaptic dysplasia, and the mechanism of the PGRN is possibly related to inhibition of the PGRN on lysosomal functions and autophagy activities in cerebells of the ASD rats.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.